Remove BMI Remove Circulation Remove Lipid disorders
article thumbnail

FDA Approves Wegovy for Cardiovascular Risk Reduction in Adults with Known Heart Disease and Overweight or Obesity

DAIC

The estimated relative risk reduction of MACE was 20% vs placebo (HR 0.80 [95% CI: 0.72, 0.90] p 1,2 The reduction of MACE with Wegovy was not impacted by age, sex, race, ethnicity, baseline BMI, or level of renal function impairment. Circulation , vol. in patients randomized to Wegovy 2.4 mg and 36.4% of patients receiving placebo.

Obesity 111